CED Member LipoScience is seeking between $65 and $75 million through an initial public offering, based on a filing with the SEC earlier this month.
This is the second time the firm has pursued an IPO option. The first was in a June 2011 filing.
If the IPO goes through as planned, LipoScience would trade on the Nasdaq under the symbol LPDX.
In the latest filing on Jan. 10, 2013, LipoScience set a target price between $13 and $15 a share for a total of five million shares.
The IPO arrives soon after the firm received FDA approval for a new test through its Vantera system this past September. LipoScience received FDA 510(k) clearance on its Vantera Clinical Analyzer.
LipoScience's venture capital investors include Durham-based CED Member Pappas Ventures.